---
title: HTN
layout: diseases
author: Corbin Cox
last-updated: 2018-12-27
created: 2018-12-26
toc: true
common: false
---

# Dx[^whelton2018]

| Category | SBP      | DBP     |
| -------- | -------- | ------- |
| Normal   | &lt; 120 | &lt; 80 |
| Elevated | 120-129  | &lt; 80 |
| Stage 1  | 130-139  | 80-89   |
| Stage 2  | &ge; 140 | &ge; 90 |

## Causes of Secondary HTN

* Renal disease
* Hyperaldosteronism
* OSA
* Drug / EtOH induced
  * Amphetamines
  * NE acting antidepressants
  * Caffeine
  * Atypical antipsychotics
  * Stimulant decongestants
  * Immunosuppressants
  * Hormonal contraceptives
  * NSAIDs
  * GCs
  * MCs
  * Angiogenesis inhibitors
  * Tyrosine Kinase inhibitors
* Pheochromocytoma
* Cushing's
* Hyper / hypothyroidism
* Aortic coarctation
* Hyperparathyroidism
* Adrenal hyperplasia
* Acromegaly

## Misc Recommendations

* Screen for primary aldosteronism in its with resistant HTN, especially those w/ hypokalemia, stroke at a young age, or FHx of early-onset HTN
* 

# Tx[^whelton2018]

* General Treatment Algorithm
  * Stage 1ASCVD Risk &lt; 10%: Non-pharm and reassess in 3-6mo
  * Otherwise, non-pharm and pharmacotherapy and reassess in 1mo
* Target &lt; 130/80 for all pts
  * Consider starting 2 drugs if in Stage 2 or &gt; 20/10 above target
  * Stroke pts w/ previously Dx HTN before stroke are the exception, target &lt; 140/90
* ACEI / ARB Best first Choice
  * SIHD (also &beta;-blockers)
  * CKD (&ge; Stage 3 or w/ significant albuminuria)
* Use CCBs and Thiazides in AA pts d/t inherently low levels of RAAS activity
* DM
  * All 1st line agents now appropriate

Non-pharm Interventions and BP Impact
{: .caption}

| Intervention      | Decrease |
| ----------------- | -------- |
| Wt loss           | 1 / kg   |
| Healthy diet      | 11       |
| Na &lt; 1500mg QD | 5-6      |
| K 3500-5000mg QD  | 4-5      |
| Exercise          | 4-8      |
| Decreased EtOH    | 4        |

First-Line Drugs and Doses
{: .caption}

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Usual Daily Dose (mg)</th>
      <th>Frequency</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td colspan="3">Thiazides</td>
    </tr>
    <tr>
      <td>Chlorthalidone</td>
      <td>12.5-25</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>HCTZ</td>
      <td>25-50</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Indapamide</td>
      <td>1.25-2.5</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Metolazone</td>
      <td>2.5-5</td>
      <td>QD</td>
    </tr>
    <tr>
      <td colspan="3">ACEIs</td>
    </tr>
    <tr>
      <td>Enalapril</td>
      <td>5-40</td>
      <td>QD or BID</td>
    </tr>
    <tr>
      <td>Lisinopril</td>
      <td>10-40</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Quinapril</td>
      <td>10-80</td>
      <td>QD or BID</td>
    </tr>
    <tr>
      <td>Ramipril</td>
      <td>2.5-20</td>
      <td>QD or BID</td>
    </tr>
    <tr>
      <td colspan="3">ARBs</td>
    </tr>
    <tr>
      <td>Candesartan</td>
      <td>8-32</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Irbesartan</td>
      <td>150-300</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Losartan</td>
      <td>50-100</td>
      <td>QD or BID</td>
    </tr>
    <tr>
      <td>Valsartan</td>
      <td>80-320</td>
      <td>QD</td>
    </tr>
    <tr>
      <td colspan="3">DHP CCBs</td>
    </tr>
    <tr>
      <td>Amlodipine</td>
      <td>2.5-10</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Nicardipine SR</td>
      <td>60-120</td>
      <td>BID</td>
    </tr>
    <tr>
      <td>Nifedipine LA</td>
      <td>30-90</td>
      <td>QD</td>
    </tr>
    <tr>
      <td colspan="3">Non-DHP CCBs</td>
    </tr>
    <tr>
      <td>Diltiazem ER</td>
      <td>120-360</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Verapamil IR</td>
      <td>120-360</td>
      <td>TID</td>
    </tr>
    <tr>
      <td>Verapamil SR</td>
      <td>120-360</td>
      <td>QD or BID</td>
    </tr>
  </tbody>
</table>




# HTN Crisis[^whelton2018]<sup>, </sup>[^benken2018]

## Dx


*  BP &gt; 180/120
*  Evidence of end-organ damage &rArr; emergency, otherwise &rArr; urgency

   *  ICH
   *  HTN encephalopathy
   *  Cerebral infarct
   *  Acute pulmonary edema
   *  Acute HF
   *  ACS
   *  AKI
   *  LFT elevation (most commonly w/ HELLP syndrome)
   *  Retinal hemorrhage
   *  Eclampsia
   *  Aortic dissection

## Tx
* Urgency
  * Restart or intensify home PO regimine w/ close f/u
* Emergency
  * IV antihypertensives
  * Target 25% BP decrease in 1hr, then 160/110 in the following 2-6hrs, then normal BP w/i 24-48hrs
  * **Pre-/eclampsia, aortic aneurism, stroke, and pheochromocytoma have special therapies**
* Ischemic Stroke
  * Treat to 185/110 before thrombolysis and 180/105 after thrombolysis
  * Treat if not thrombolysing and have evidence of end-organ damage or &gt; 220/120

IV Antihypertensives
{: .caption}

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Initial Dose</th>
      <th>Max Dose</th>
      <th>Onset</th>
      <th>Duration</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td colspan="6">CCBs</td>
    </tr>
    <tr>
      <td>Nicardipine</td>
      <td>5 mg/hr<br>Increase 2.5 mg/hr Q5-10min</td>
      <td>15mg/hr</td>
      <td>5-10min</td>
      <td>2-6hr</td>
      <td>CI in advanced aortic stenosis</td>
    </tr>
    <tr>
      <td>Clevidipine</td>
      <td>1-6mg/hr<br>Titrate 1-2 mg/hr Q90s</td>
      <td>32mg/h<br>72hr use</td>
      <td>1-4min</td>
      <td>5-15min</td>
      <td>Low end of range in elderly</td>
    </tr>
    <tr>
      <td colspan="6">Vasodilators</td>
    </tr>
    <tr>
      <td>Nitroprusside</td>
      <td>0.25-0.5 mcg/kg/min<br>Titrate 0.1-0.2 mcg/kg/min Q5-10min</td>
      <td>10 mcg/kg/min</td>
      <td>Seconds</td>
      <td>1-2min</td>
      <td>Give thiosulfate to prevent CN poisoning if &gt; 30min or ≥ 4 mcg/kg/min</td>
    </tr>
    <tr>
      <td>NTG</td>
      <td>5 mcg/min<br>Titrate by 0.1-0.2 mcg/kg/min Q5min</td>
      <td>200 mcg/min</td>
      <td>2-5min</td>
      <td>5-10min</td>
      <td>Preferred in ACS or acute pulmonary edema<br>CI in volume dependent states (e.g. right-ventricular infarct)</td>
    </tr>
    <tr>
      <td>Hydralazine</td>
      <td>10mg slow IV infusion Q4-6hr<br>IM: 10mg Q30min</td>
      <td>20mg initial<br>IM: 40mg</td>
      <td>IV: 10min<br>IM: 20min</td>
      <td>IV: 1-4hr<br>IM: 2-6hr</td>
      <td>Highly unpredictable<br>10-30min to start, and lasts 4-6hr</td>
    </tr>
    <tr>
      <td colspan="6">β-Blockers</td>
    </tr>
    <tr>
      <td>Esmolol</td>
      <td>500-1000 mcg/kg over 1min then 50 mcg/kg/min infusion<br>Titrate 25 mcg/kg/min Q3-5min</td>
      <td>200 mcg/kg/min</td>
      <td>1-2min</td>
      <td>10-20min</td>
      <td>β<sub>1</sub> selective<br>Don’t use in HF, other β-blocker use, or existing bradycardia / heart block</td>
    </tr>
    <tr>
      <td>Labetalol</td>
      <td>0.3-1 mg/kg (20-80mg) Q5-10min<br>or<br>0.4-1 mg/kg/hr (0.5-10 mg/min)</td>
      <td>Titrate infusion by 1-2mg/min Q2hr</td>
      <td>2-5min (peak 5-15min)</td>
      <td>2-6hr (up to 18hr in some pts)</td>
      <td>Non-selective blockade<br>CI in reactive airway disease<br>Avoid in heart block / bradycardia / HF</td>
    </tr>
    <tr>
      <td>Metoprolol</td>
      <td>5-15mg Q5-15min</td>
      <td>&nbsp;</td>
      <td>5-20min</td>
      <td>2-6hr</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td colspan="6">α-Blockers</td>
    </tr>
    <tr>
      <td>Phentolamine</td>
      <td>5mg Q10min PRN</td>
      <td>&nbsp;</td>
      <td>Seconds</td>
      <td>15min</td>
      <td>Most useful in catecholamine excess (pheochromocytoma, MAOI interactions, cocaine / amphetamine overdose, etc)</td>
    </tr>
    <tr>
      <td colspan="6">D<sub>1</sub> Antagonist</td>
    </tr>
    <tr>
      <td>Fenoldopam</td>
      <td>0.1-0.3 mcg/kg/min</td>
      <td>Increase 0.05-0.1 mch/kh/min Q15min to target BP NTE 1.6 mcg/kg/min</td>
      <td>10-15min</td>
      <td>10-15min</td>
      <td>CI in pts w/ increase IOP or ICP or sulfite allergy</td>
    </tr>
    <tr>
      <td colspan="6">ACEI</td>
    </tr>
    <tr>
      <td>Enalaprilat</td>
      <td>1.25mg over 5min</td>
      <td>Increase 5mg Q6h PRN</td>
      <td>15-30min</td>
      <td>12-24hr</td>
      <td>CI in pregnancy, bilateral renal artery stenosis, acute MI<br>Slow onset (15min)<br>Unpredictable</td>
    </tr>
  </tbody>
</table>
Preferred Agents in Specific Circumstances[^whelton2018]
{: .caption}

| Condition                                                    | Preferred Drug                          | Notes                                                        |
| ------------------------------------------------------------ | --------------------------------------- | ------------------------------------------------------------ |
| Aortic Dissection                                            | Esmolol, labetolol                      | Rapidly lower to SBP &le; 120 w/i 20min<br />If needed, can add vasodilator, but must add rate-control first |
| Acute Pulmonary Edema                                        | Clevidipine, NTG, nitropruside          | &beta;-blockers CI                                           |
| ACS                                                          | Esmolol, labetolol, nicardipine, NTG    | Watch for PDE inhibitors if giving nitrate based therapy     |
| Acute renal Failure                                          | Clevidipine, fenoldopam, nicardipine    |                                                              |
| Pre-/Eclampsia                                               | Hydralazine, labetolol, nicardipine     | Lower rapidly                                                |
| Perioperative HTN                                            | Clevidipine, esmolol, nicardipine, NTG  |                                                              |
| Sympathetic Excess (cocaine, amphetamines, pheochromocytoma, etc) | Clevidipine, nicardipine, phenotolomine |                                                              |

IV Antihypertensive Hemodynamic Effects
{: .caption}

| Drug             | Preload | Afterload | CO   |
| ---------------- | ------- | --------- | ---- |
| CCBs             |         |           |      |
| Nicardipine | &harr; | &darr; | &uarr; |
| Clevidipine | &harr; | &darr; | &uarr; |
| Vasodilators     |         |           |      |
| Nitroprusside | &darr; | &darr;&darr; | &uarr; |
| NTG | &darr;&darr; | &darr;&harr; | &harr;&uarr; |
| Hydralazine | &harr; | &darr; | &uarr; |
| &beta;-Blockers  |         |           |      |
| Esmolol | &harr; | &harr; | &darr; |
| Labetolol | &harr; | &darr; | &darr; |
| Metoprolol | &harr; | &harr; | &darr; |
| &alpha;-Blockers |         |           |      |
| Phentolamine | &harr; | &darr; | &uarr; |
| D<sub>1</sub> Antagonists |         |           |      |
| Fenoldopam | &harr;&darr; | &darr; | &uarr; |
| ACEI | | | |
| Enalaprilat | &darr; | &darr; | &uarr; |




# References

{% include sources.md %}
